AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc.
Washington University School of Medicine
Hoffmann-La Roche
Columbia University
Juno Therapeutics, a Subsidiary of Celgene
Merck Sharp & Dohme LLC
Fate Therapeutics
University of Arizona
Fate Therapeutics
Incyte Corporation
Incyte Corporation
PrECOG, LLC.
Emory University
Incyte Corporation
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Insel Gruppe AG, University Hospital Bern
Polish Lymphoma Research Group
German CLL Study Group
German CLL Study Group
German CLL Study Group
Cyteir Therapeutics, Inc.
Cedars-Sinai Medical Center
St. Petersburg State Pavlov Medical University
Damanhour University
University of Giessen
University of Giessen
AbbVie
Corewell Health West
M.D. Anderson Cancer Center
Seagen Inc.
Gilead Sciences
St. Petersburg State Pavlov Medical University
Wake Forest University Health Sciences
Celgene
Washington University School of Medicine
Hoffmann-La Roche
Eastern Cooperative Oncology Group
University of Wisconsin, Madison
Teva Branded Pharmaceutical Products R&D, Inc.
Brown University
International Extranodal Lymphoma Study Group (IELSG)
Hoffmann-La Roche
Hoffmann-La Roche
Fondazione Italiana Linfomi - ETS